Welcome to LookChem.com Sign In|Join Free
  • or
1-Piperonylpiperazine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

32231-06-4

Post Buying Request

32231-06-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

32231-06-4 Usage

Chemical Properties

white to yellow or yellow-brownish cryst. solid

Uses

1-Piperonylpiperazine (cas# 32231-06-4) is a compound useful in organic synthesis.

General Description

The effect of 1-piperonylpiperazine on 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity was studied.

Check Digit Verification of cas no

The CAS Registry Mumber 32231-06-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,2,2,3 and 1 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 32231-06:
(7*3)+(6*2)+(5*2)+(4*3)+(3*1)+(2*0)+(1*6)=64
64 % 10 = 4
So 32231-06-4 is a valid CAS Registry Number.
InChI:InChI=1/C12H16N2O2/c1-2-11-12(16-9-15-11)7-10(1)8-14-5-3-13-4-6-14/h1-2,7,13H,3-6,8-9H2/p+2

32231-06-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (L15625)  1-Piperonylpiperazine, 97%   

  • 32231-06-4

  • 5g

  • 281.0CNY

  • Detail
  • Alfa Aesar

  • (L15625)  1-Piperonylpiperazine, 97%   

  • 32231-06-4

  • 25g

  • 968.0CNY

  • Detail
  • Aldrich

  • (224952)  1-Piperonylpiperazine  97%

  • 32231-06-4

  • 224952-25G

  • 1,079.91CNY

  • Detail

32231-06-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(1,3-benzodioxol-5-ylmethyl)piperazine

1.2 Other means of identification

Product number -
Other names EINECS 250-968-5

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:32231-06-4 SDS

32231-06-4Synthetic route

piperazine
110-85-0

piperazine

piperonol
495-76-1

piperonol

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

Conditions
ConditionsYield
In o-xylene at 150℃; for 30h; Inert atmosphere; Sealed tube;81%
With aluminum (III) chloride; water In acetonitrile at 20℃; Irradiation;41%
1-(1,3-benzodioxol-5-ylmethyl)-4-[(2-nitrophenyl)methyl]piperazine

1-(1,3-benzodioxol-5-ylmethyl)-4-[(2-nitrophenyl)methyl]piperazine

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

Conditions
ConditionsYield
With hydrazine In 1,4-dioxane; water Inert atmosphere; UV-irradiation;80%
piperazine
110-85-0

piperazine

piperonal
120-57-0

piperonal

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

Conditions
ConditionsYield
With palladium 10% on activated carbon; hydrogen In tert-butyl methyl ether at 13 - 18℃; High pressure;78%
piperazine
110-85-0

piperazine

5-(chloromethyl)-1,3-benzodioxole
20850-43-5

5-(chloromethyl)-1,3-benzodioxole

piperazine dihydrochloride
142-64-3

piperazine dihydrochloride

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

Conditions
ConditionsYield
Stage #1: piperazine; piperazine dihydrochloride In ethanol at 65℃; for 1h;
Stage #2: 5-(chloromethyl)-1,3-benzodioxole In ethanol at 78℃; for 2h;
benzyl 4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-carboxylate

benzyl 4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-carboxylate

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

Conditions
ConditionsYield
With palladium 10% on activated carbon; hydrogen In methanol at 20℃; for 2h;
4-chloro-6-dimethylamino-3-methylisoxazolo[5,4-d]pyrimidine
724428-97-1

4-chloro-6-dimethylamino-3-methylisoxazolo[5,4-d]pyrimidine

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

6-dimethylamino-3-methyl-4-(3,4-methylenedioxybenzylpiperazino)isoxazolo[5,4-d]pyrimidine

6-dimethylamino-3-methyl-4-(3,4-methylenedioxybenzylpiperazino)isoxazolo[5,4-d]pyrimidine

Conditions
ConditionsYield
In tetrahydrofuran Heating;99%
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

tert-butyl 4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-carboxylate
1233143-33-3

tert-butyl 4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-carboxylate

Conditions
ConditionsYield
With triethylamine In methanol at 20℃; for 1.5h; Inert atmosphere;99%
p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

1-(benzo[d][1,3]dioxol-5-ylmethyl)-4-tosylpiperazine
305859-64-7

1-(benzo[d][1,3]dioxol-5-ylmethyl)-4-tosylpiperazine

Conditions
ConditionsYield
With triethylamine In tetrahydrofuran at 20℃; for 4.5h; Inert atmosphere;99%
carbon dioxide
124-38-9

carbon dioxide

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

C13H16N2O3

C13H16N2O3

Conditions
ConditionsYield
With hydrogen In methanol at 120℃; under 30003 Torr; for 24h; Autoclave;99%
dimethyl acetylenedicarboxylate
762-42-5

dimethyl acetylenedicarboxylate

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

tetramethyl 2,2'-(1,4-piperazindiyl)dimaleate
24726-53-2

tetramethyl 2,2'-(1,4-piperazindiyl)dimaleate

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 20℃; for 1h;98%
2-chloropyrimidine
1722-12-9

2-chloropyrimidine

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

piribedil
3605-01-4

piribedil

Conditions
ConditionsYield
With C50H61Cl2N3Pd; potassium tert-butylate In 1,4-dioxane at 100℃; for 2h;98%
With C48H55ClN2Pd; sodium t-butanolate In 1,2-dimethoxyethane at 20℃; for 16h; Inert atmosphere; Sealed tube;98%
With potassium carbonate In tetrahydrofuran for 2h; Reflux;44%
4,6-dichloro-2,8-bis(dimethylamino)-5-phenyl-5H-thiopyrano[2,3-d:6,5-d']dipyrimidine
259654-07-4

4,6-dichloro-2,8-bis(dimethylamino)-5-phenyl-5H-thiopyrano[2,3-d:6,5-d']dipyrimidine

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

6-chloro-2,8-bis(dimethylamino)-5-phenyl-4-(4-piperonylpiperazino)-5H-thiopyrano[2,3-d:6,5-d']dipyrimidine
259654-13-2

6-chloro-2,8-bis(dimethylamino)-5-phenyl-4-(4-piperonylpiperazino)-5H-thiopyrano[2,3-d:6,5-d']dipyrimidine

Conditions
ConditionsYield
In tetrahydrofuran Substitution; Heating;95%
p-tolylsulfinyl amide
6873-55-8

p-tolylsulfinyl amide

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

C19H22N2O3S

C19H22N2O3S

Conditions
ConditionsYield
With europium(III) trifluoromethanesulfonate In acetonitrile at 50℃; for 24h; Inert atmosphere; Schlenk technique;95%
acetic anhydride
108-24-7

acetic anhydride

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

1-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)ethanone

1-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)ethanone

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 13h; Inert atmosphere;94%
(3αS,5αS,9βS)-5α,9-dimethyl-3-methylene-3α,5,5α,9β-tetrahydronaphtho[1,2-β]furan-2,8(3H,4H)-dione
66726-11-2

(3αS,5αS,9βS)-5α,9-dimethyl-3-methylene-3α,5,5α,9β-tetrahydronaphtho[1,2-β]furan-2,8(3H,4H)-dione

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

(3aS,5aS,9bS)-3-(4-benzo[1,3]dioxol-5-ylmethylpiperazin-1-ylmethyl)-5a,9-dimethyl-3a,5,5a,9b-tetrahydro-3H,4H-naphtho[1,2-b]furan-2,8-dione
1217269-74-3

(3aS,5aS,9bS)-3-(4-benzo[1,3]dioxol-5-ylmethylpiperazin-1-ylmethyl)-5a,9-dimethyl-3a,5,5a,9b-tetrahydro-3H,4H-naphtho[1,2-b]furan-2,8-dione

Conditions
ConditionsYield
In methanol at 20℃; Michael reaction; stereospecific reaction;94%
acrylonitrile
107-13-1

acrylonitrile

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

3-[4-[(benzo[1,3]dioxol-5-yl)methyl]piperazin-1-yl]propionitrile
385371-21-1

3-[4-[(benzo[1,3]dioxol-5-yl)methyl]piperazin-1-yl]propionitrile

Conditions
ConditionsYield
With triethylammonium acetate at 25℃; for 0.0166667h; Aza-Michael reaction; chemoselective reaction;93%
With multi-walled carbon nanotubes-triethylammonium hydrogen phosphate composite at 25℃; for 0.0166667h; Michael Addition; Green chemistry;93%
With single-walled carbon nanotube-triethylammonium hydrogen phosphate ionic liquid at 25℃; for 0.0166667h;94 %Chromat.
1-benzyl-1H-pyrrole-2,5-dione
1631-26-1

1-benzyl-1H-pyrrole-2,5-dione

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

3-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-1-benzylpyrrolidine-2,5-dione

3-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-1-benzylpyrrolidine-2,5-dione

Conditions
ConditionsYield
With triethylamine; lithium chloride In tetrahydrofuran at 23℃; for 1.5h; chemoselective reaction;93%
6-(2-bromoacetyl)-3-methylbenzo[d]oxazol-2(3H)-one
79851-85-7

6-(2-bromoacetyl)-3-methylbenzo[d]oxazol-2(3H)-one

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

6-[2-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-acetyl]-3-methyl-3H-benzooxazol-2-one

6-[2-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-acetyl]-3-methyl-3H-benzooxazol-2-one

Conditions
ConditionsYield
With triethylamine In 1,4-dioxane for 8h; Ambient temperature;92%
6-benzoyl-2(3H)-benzoxazolone
54903-12-7

6-benzoyl-2(3H)-benzoxazolone

formaldehyd
50-00-0

formaldehyd

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

3-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-ylmethyl)-6-benzoyl-3H-benzooxazol-2-one

3-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-ylmethyl)-6-benzoyl-3H-benzooxazol-2-one

Conditions
ConditionsYield
In methanol for 1h; Heating;92%
formaldehyd
50-00-0

formaldehyd

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

1-(benzo[d][1,3]dioxol-5-ylmethyl)-4-methylpiperazine
55500-12-4

1-(benzo[d][1,3]dioxol-5-ylmethyl)-4-methylpiperazine

Conditions
ConditionsYield
Stage #1: formaldehyd; 1-Piperonylpiperazine With sodium tris(acetoxy)borohydride; triethylamine In dichloromethane; water at 20℃; for 16.5h;
Stage #2: With sodium hydrogencarbonate In dichloromethane; water
92%
Cholesteryl chloroformate
7144-08-3

Cholesteryl chloroformate

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

cholest-5-en-3-yl 4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinecarboxylate
1120327-24-3

cholest-5-en-3-yl 4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinecarboxylate

Conditions
ConditionsYield
With triethylamine In dichloromethane at 0 - 20℃; Inert atmosphere;92%
2,6-Dichloropyrimidine
3934-20-1

2,6-Dichloropyrimidine

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

piribedil
3605-01-4

piribedil

Conditions
ConditionsYield
With C34H52BrN3OPd In 1,4-dioxane at 90℃; for 3h; Inert atmosphere; Schlenk technique;92%
benzyl bromide
100-39-0

benzyl bromide

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

1-(benzo[d][1,3]dioxol-5-ylmethyl)-4-benzylpiperazine
414876-23-6

1-(benzo[d][1,3]dioxol-5-ylmethyl)-4-benzylpiperazine

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 18.5h; Inert atmosphere;91%
2-Benzoxazolinone
59-49-4

2-Benzoxazolinone

formaldehyd
50-00-0

formaldehyd

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

3-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-ylmethyl)-3H-benzooxazol-2-one

3-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-ylmethyl)-3H-benzooxazol-2-one

Conditions
ConditionsYield
In methanol for 1h; Heating;90%
3-(4-chlorobutyl)-1,2,3-benzotriazin-4(3H)-one
158659-66-6

3-(4-chlorobutyl)-1,2,3-benzotriazin-4(3H)-one

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

3-[4-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-butyl]-3H-benzo[d][1,2,3]triazin-4-one; hydrochloride

3-[4-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-butyl]-3H-benzo[d][1,2,3]triazin-4-one; hydrochloride

Conditions
ConditionsYield
With potassium carbonate; sodium iodide In N,N-dimethyl-formamide at 80 - 120℃; for 1.16667h; microwave irradiation;90%
2-chloro-N-(4,5-dihydro-1-methyl-[1,2,4]-triazolo[4,3-a]quinolin-7-yl)acet-amide
1064703-56-5

2-chloro-N-(4,5-dihydro-1-methyl-[1,2,4]-triazolo[4,3-a]quinolin-7-yl)acet-amide

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

C25H28N6O3
1064703-58-7

C25H28N6O3

Conditions
ConditionsYield
With sodium carbonate In methanol for 10h; Reflux;90%
7-chloro-1-(2,4-difluorophenyl)-1,4-dihydro-8-methyl-6-nitro-4-oxoquinolone-3-carboxylic acid
1146300-32-4

7-chloro-1-(2,4-difluorophenyl)-1,4-dihydro-8-methyl-6-nitro-4-oxoquinolone-3-carboxylic acid

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

7-(4-((benzo[d][1,3]dioxol-5-yl)methyl)piperazin-1-yl)-1-(2,4-difluorophenyl)-1,4-dihydro-8-methyl-6-nitro-4-oxoquinoline-3-carboxylic acid
1146300-53-9

7-(4-((benzo[d][1,3]dioxol-5-yl)methyl)piperazin-1-yl)-1-(2,4-difluorophenyl)-1,4-dihydro-8-methyl-6-nitro-4-oxoquinoline-3-carboxylic acid

Conditions
ConditionsYield
With potassium carbonate In dimethyl sulfoxide Microwave irradiation;90%
6-(bromomethyl)-5-chloro-2-(thiophen-2-yl)-7,8-dihydroquinoline

6-(bromomethyl)-5-chloro-2-(thiophen-2-yl)-7,8-dihydroquinoline

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

6-((4-(benzo[d] [1,3]dioxol-5-ylmethyl)piperazinyl)methyl)-5-chloro-2-(thiophen-2-yl)-7,8-dihydroquinoline

6-((4-(benzo[d] [1,3]dioxol-5-ylmethyl)piperazinyl)methyl)-5-chloro-2-(thiophen-2-yl)-7,8-dihydroquinoline

Conditions
ConditionsYield
With potassium carbonate In acetone at 20℃; for 12h;90%
1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

thioctic acid-N-hydroxysuccinimide ester
40846-94-4

thioctic acid-N-hydroxysuccinimide ester

1-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-5-(1,2-dithiolan-3-yl)pentan-1-one

1-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-5-(1,2-dithiolan-3-yl)pentan-1-one

Conditions
ConditionsYield
In dichloromethane at 20℃; for 5h; Inert atmosphere;89%
4-Fluoronitrobenzene
350-46-9

4-Fluoronitrobenzene

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

1-benzo[1,3]dioxol-5-ylmethyl-4-(4-nitro-phenyl)-piperazine

1-benzo[1,3]dioxol-5-ylmethyl-4-(4-nitro-phenyl)-piperazine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 20℃;89%
N-(3-chloropropyl)isonicotinamide

N-(3-chloropropyl)isonicotinamide

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

N-(3-(4-(piperonyl)piperazin-1-yl)propyl)isonicotinamide

N-(3-(4-(piperonyl)piperazin-1-yl)propyl)isonicotinamide

Conditions
ConditionsYield
Stage #1: N-(3-chloropropyl)isonicotinamide With sodium iodide In acetonitrile at 70℃; for 0.5h;
Stage #2: 1-Piperonylpiperazine With potassium carbonate In acetonitrile at 70℃; for 24h;
89%
(R,2E,4E)-6-((tert-butyldimethylsilyl)oxy)-7-(3,4-dimethoxyphenyl)hepta-2,4-dienoic acid
1448848-29-0

(R,2E,4E)-6-((tert-butyldimethylsilyl)oxy)-7-(3,4-dimethoxyphenyl)hepta-2,4-dienoic acid

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

(R,2E,4E)-1-(4-(benzo[1,3]dioxol-5-ylmethyl)piperazin-1-yl)-6-((tert-butyldimethylsilyl)oxy)-7-(3,4-dimethoxyphenyl)-hepta-2,4-dien-1-one

(R,2E,4E)-1-(4-(benzo[1,3]dioxol-5-ylmethyl)piperazin-1-yl)-6-((tert-butyldimethylsilyl)oxy)-7-(3,4-dimethoxyphenyl)-hepta-2,4-dien-1-one

Conditions
ConditionsYield
Stage #1: (R,2E,4E)-6-((tert-butyldimethylsilyl)oxy)-7-(3,4-dimethoxyphenyl)hepta-2,4-dienoic acid With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 0 - 20℃; Inert atmosphere;
Stage #2: 1-Piperonylpiperazine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;
89%
1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)pyrazine

2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)pyrazine

Conditions
ConditionsYield
With iodine; sodium acetate In acetonitrile at 70℃;89%
2-chloro-N-(4-sulfamoylbenzyl)acetamide
101167-02-6

2-chloro-N-(4-sulfamoylbenzyl)acetamide

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-N-(4-sulfamoylbenzyl)acetamide

2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-N-(4-sulfamoylbenzyl)acetamide

Conditions
ConditionsYield
With sodium carbonate In N,N-dimethyl-formamide at 100 - 120℃; Reflux;89%
formaldehyd
50-00-0

formaldehyd

propargyl ether mycophenolate

propargyl ether mycophenolate

1-Piperonylpiperazine
32231-06-4

1-Piperonylpiperazine

mycophenoyl methyl ester-7-(butynyloxy-N-(piperonylpiperazine))

mycophenoyl methyl ester-7-(butynyloxy-N-(piperonylpiperazine))

Conditions
ConditionsYield
With copper(l) iodide In 1,4-dioxane at 120℃; for 1h;89%

32231-06-4Relevant academic research and scientific papers

Design, synthesis and SAR of antitubercular benzylpiperazine ureas

Satish, Sohal,Chitral, Rohan,Kori, Amitkumar,Sharma, Basantkumar,Puttur, Jayashree,Khan, Afreen A.,Desle, Deepali,Raikuvar, Kavita,Korkegian, Aaron,Martis, Elvis A. F.,Iyer, Krishna R.,Coutinho, Evans C.,Parish, Tanya,Nandan, Santosh

, (2021/01/04)

Abstract: N-furfuryl piperazine ureas disclosed by scientists at GSK Tres Cantos were chosen as antimycobacterial hits from a phenotypic whole-cell screen. Bioisosteric replacement of the furan ring in the GSK Tres Cantos molecules with a phenyl ring led to molecule (I) with an MIC of 1?μM against Mtb H37Rv, low cellular toxicity (HepG2 IC50 ~ 80?μM), good DMPK properties and specificity for Mtb. With the aim of delineating the SAR associated with (I), fifty-five analogs were synthesized and screened against Mtb. The SAR suggests that the piperazine ring, benzyl urea and piperonyl moieties are essential signatures of this series. Active compounds in this series are metabolically stable, have low cellular toxicity and are valuable leads for optimization. Molecular docking suggests these molecules occupy the Q0 site of QcrB like Q203. Graphic Abstract: Bioisosteric replacement of N-furfuryl piperazine-1-carboxamides yielded molecule (I) a novel lead with satisfactory PD, metabolism, and toxicity profiles.[Figure not available: see fulltext.]

Photocatalytic Water-Splitting Coupled with Alkanol Oxidation for Selective N-alkylation Reactions over Carbon Nitride

Xu, Yangsen,Zhang, Zhaofei,Qiu, Chuntian,Chen, Shaoqin,Ling, Xiang,Su, Chenliang

, p. 582 - 589 (2020/12/09)

Photocatalytic water splitting technology (PWST) enables the direct use of water as appealing “liquid hydrogen source” for transfer hydrogenation reactions. Currently, the development of PWST-based transfer hydrogenations is still in an embryonic stage. Previous reports generally centered on the rational utilization of the in situ generated H-source (electrons) for hydrogenations, in which photogenerated holes were quenched by sacrificial reagents. Herein, the fully-utilization of the liquid H-source and holes during water splitting is presented for photo-reductive N-alkylation of nitro-aromatic compounds. In this integrate system, H-species in situ generated from water splitting were designed for nitroarenes reduction to produce amines, while alkanols were oxidized by holes for cascade alkylating of anilines as well as the generated secondary amines. More than 50 examples achieved with a broad range scope validate the universal applicability of this mild and sustainable coupling approach. The synthetic utility of this protocol was further demonstrated by the synthesis of existing pharmaceuticals via selective N-alkylation of amines. This strategy based on the sustainable water splitting technology highlights a significant and promising route for selective synthesis of valuable N-alkylated fine chemicals and pharmaceuticals from nitroarenes and amines with water and alkanols.

Scalable preparation of stable and reusable silica supported palladium nanoparticles as catalysts for N-alkylation of amines with alcohols

Alshammari, Ahmad S.,Natte, Kishore,Kalevaru, Narayana V.,Bagabas, Abdulaziz,Jagadeesh, Rajenahally V.

, p. 141 - 149 (2020/01/06)

The development of nanoparticles-based heterogeneous catalysts continues to be of scientific and industrial interest for the advancement of sustainable chemical processes. Notably, up-scaling the production of catalysts to sustain unique structural features, activities and selectivities is highly important and remains challenging. Herein, we report the expedient synthesis of Pd-nanoparticles as amination catalysts by the reduction of simple palladium salt on commercial silica using molecular hydrogen. The resulting Pd-nanoparticles constitute stable and reusable catalysts for the synthesis of various N-alkyl amines using borrowing hydrogen technology without the use of any base or additive. By applying this Pd-based catalyst, functionalized and structurally diverse N-alkylated amines as well as some selected drug molecules were synthesized in good to excellent yields. Practical and synthetic utility of this Pd-based amination protocol has been demonstrated by upscaling catalyst preparation and amination reactions to several grams-scales as well as recycling of catalyst. Noteworthy, this Pd-catalyst preparation has been up-scaled to kilogram scale and catalysts prepared in both small (1 g) and large-scale (kg) exhibited similar structural features and activity.

Synthetic method of piribedil

-

Paragraph 0014, (2017/04/03)

The invention relates to a synthetic method of piribedil. The synthetic method is a brand new process comprising the steps of synthesizing piperonyl piperazine in one step under the effects of pentamethyleneamine, piperazine pyrimidine and paraformaldehyde, and reacting by virtue of piperonyl piperazine and dichloropyrimidine so as to synthesize piribedil. Piperonyl piperazine has not been synthesized by virtue of the synthetic method before. Compared with a traditional synthetic method of piribedil, the synthetic method has the advantages that synthetic steps are simplified, the three wastes are reduced, the utilization ratio of pentamethyleneamine is remarkably increased, and the after-treatment is relatively environment-friendly.

PLANT GROWTH-PROMOTION AGENT AND METHOD FOR PROMOTING PLANT GROWTH

-

Paragraph 0139; 0141; 0142; 0143, (2017/11/11)

The present invention concerns: a plant growth-promoting agent comprising a compound represented by Formula (I) or a salt thereof: wherein Ar1 represents a substituted or unsubstituted phenyl group, NZ represents a nitrogen-containing heterocyclic ring group or an acyclic nitrogen-containing group having a partial structure of the nitrogen-containing heterocyclic ring group, n is 0, 1, or 2, R1 and R2 each represent a hydrogen atom, a substituted or unsubstituted C1-3-alkyl group, a cyano group, or a carboxyl group, R1 and R2 may together form an oxo group, and when n is 2, R1 or R2 may be the same or different; and a method for promoting plant growth using the plant growth-promoting agent.

Reevaluation of the 2-nitrobenzyl protecting group for nitrogen containing compounds: An application of flow photochemistry

Wendell, Chloe I.,Boyd, Michael J.

supporting information, p. 897 - 899 (2015/02/05)

Photochemistry under continuous flow conditions has many potential benefits for photochemical reactions that are problematic in batch. The 2-nitrobenzyl moiety is a photolabile protecting group for nitrogen. However, N-deprotection is generally impractical and, therefore, has not been extensively adopted. This Letter reports significant improvements in the N-deprotection of the 2-nitrobenzyl group through the application of continuous flow photolysis. This procedure was applied to a variety of substrates including indoles, indazoles, pyrazoles and secondary amines. Significant improvement in yield, reaction time and scalability was observed under continuous flow conditions.

Synthesis and antimalarial activity of hydroxyethylpiperazine derivatives

Cunico, Wilson,Gomes, Claudia R.B.,Moreth, Marcele,Manhanini, Diogo P.,Figueiredo, Isabela H.,Penido, Carmen,Henriques, Maria G.M.O.,Varotti, Fernando P.,Krettli, Antoniana U.

body text, p. 1363 - 1368 (2009/09/27)

The antimalarial activity of hydroxyethylpiperazine derivatives, synthesized from the reaction of (2S,3S)Boc-phenylalanine epoxide with benzylpiperazines in good yields (76-96%), has been evaluated in vitro against the Plasmodium falciparum W2 clone (chlo

PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE

-

Page/Page column 91, (2008/06/13)

Compounds of formula (I) : wherein, Z is -N-or>CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring member with one or two Ra moieties; Wher each Ra moiety is independently selected from the group consisting of -C1-4alkyl, -C2-4alkenyl, -OH, -OC1-4alkyl, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkyl, -OSO2C1-4alkyl, -CO2C1-4alkyl, -CO2H, -COC1-4alkyl, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, and -CN, wherein Rb and Rc are each independently -H or -C1-4alkyl; and Ar2 is defined in the claims are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same

-

, (2008/06/13)

Oligomeric compounds comprising a plurality of aminodiol monomer subunits joined by linking groups are provided, as well as libraries of such compounds and processes for preparing the oligomeric compounds and libraries.

Pharmaceutically active pyrrolidine derivatives as bax inhibitors

-

, (2008/06/13)

The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CRR, NOR, NNRR; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2-, —SO2NH—; —CH2-; B is either a group —(C═O)—NRR or represents a heterocyclic residue having the formula (II) wherein Q is NR, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 32231-06-4